Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

990.33
+7.070.72%
Post-market: 985.00-5.3300-0.54%19:59 EST
Volume:2.63M
Turnover:2.59B
Market Cap:936.24B
PE:43.15
High:991.22
Open:975.00
Low:966.09
Close:983.26
52wk High:1,133.95
52wk Low:623.78
Shares:945.38M
Float Shares:945.00M
Volume Ratio:0.82
T/O Rate:0.28%
Dividend:6.00
Dividend Rate:0.61%
EPS(TTM):22.95
EPS(LYR):22.95
ROE:101.16%
ROA:19.42%
PB:35.28
PE(LYR):43.15

Loading ...

Bridgewater Associates' 4Q Buying and Selling -- Barron's

Dow Jones
·
Feb 21

Eli Lilly & Co. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Feb 21

Top Calls on Wall Street: Apple, Microsoft, Netflix, Broadcom, CoreWeave, Eli Lilly, Walmart, and More

Tiger Newspress
·
Feb 20

Eli Lilly Initiated at Overweight by Barclays

Dow Jones
·
Feb 20

Eli Lilly Stock (LLY) Rises as Company Reports Progress with Crohn’s Disease Treatment

TIPRANKS
·
Feb 20

Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions

Reuters
·
Feb 20

Eli Lilly initiated with an Overweight at Barclays

TIPRANKS
·
Feb 20

Eli Lilly announces long-term data on Omvoh in Crohn’s disease

TIPRANKS
·
Feb 20

Lilly Says Omvoh Maintains Steroid-Free Remission for Three Years in Crohn’s Disease Patients

Reuters
·
Feb 20

Eli Lilly - Over 90% Maintained Steroid-Free Control Through Three Years

THOMSON REUTERS
·
Feb 20

Eli Lilly Pushes Into Opioid Use Disorder With New Brenipatide Phase 2 Trial

TIPRANKS
·
Feb 20

Berenberg Adjusts Price Target on Eli Lilly to $1,050 From $950, Maintains Hold Rating

MT Newswires Live
·
Feb 19

Three multinationals pay almost half of all Irish corporate tax, watchdog says

Reuters
·
Feb 19

U.S. RESEARCH ROUNDUP-EBay, Huntsman, Palo Alto

Reuters
·
Feb 19

Eli Lilly : Berenberg Raises Target Price to $1050 From $950

THOMSON REUTERS
·
Feb 19

Eli Lilly Stock (LLY) in Focus as Zepbound Found to Help Treat Psoriasis

TIPRANKS
·
Feb 18

BRIEF-Lilly's Taltz (Ixekizumab) And Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy In First-Of-Its-Kind Phase 3B Trial

Reuters
·
Feb 18

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study

Reuters
·
Feb 18

Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Delivered Superior Efficacy in First-of-Its-Kind Phase 3B Trial for Adults With Psoriasis and Obesity or Overweight

THOMSON REUTERS
·
Feb 18

Eli Lilly: Taltz, Zepbound Met Primary Endpoint of Superiority VS. Taltz Monotherapy in Achieving Complete Skin Clearance, ≥10% Weight Loss

THOMSON REUTERS
·
Feb 18